Medtronic plc (MDT) fair value analysis

S&P 500 · Updated 2026-09-07

Medtronic plc is a medical technology company that develops, manufactures, and sells devices and therapies used in cardiac surgery, neurosurgery, spinal surgery, diabetes management, and other areas of medicine. The company operates globally with a significant presence in North America, Europe, and Asia-Pacific regions.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, MDT is trading at within about 10% of estimated fair value.

MDT currently ranks #64 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $94.17
Sector: Healthcare
12-month range: $73.98–$103.34

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Moderate
Margin trend: Contracting
Revenue growth: Modest
RSI zone: Neutral
52-week position: The upper-middle quarter of its range
DCF cross-check: Overvalued

What our data shows for MDT

Our model validated 17 trailing price-to-earnings windows for MDT, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $73.98–$103.34.
The 14-day relative strength index sits at a neutral 69.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for MDT
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent MDT news

TickrTrends' derived news-sentiment signal for MDT is currently leaning positive, computed from recent coverage.

Medtronic plc (MDT) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript (seekingalpha.com, 2026-09-08)
MDT SWOT Analysis: Strong Financial Growth Revealed in 10-Q Filing (gurufocus.com, 2026-09-04)
TickrTrends take: MDT's strong financial growth as detailed in its recent 10-Q filing provides substantive data for valuation assessment in the Healthcare sector. With TickrTrends currently assessing MDT as fairly valued, investors monitoring the company should track whether this demonstrated financial growth trajectory can sustain momentum or if it becomes reflected in adjusted valuation metrics over coming periods. The relationship between the company's operational performance and its current valuation baseline will be important for those seeking to understand whether the fair value assessment remains appropriately calibrated.
MDT Maintained by UBS -- Price Target Raised to $110 (gurufocus.com, 2026-09-03)
TickrTrends take: UBS maintained its stance on Medtronic while lifting its price target to $110, signaling confidence in the company's trajectory within the Healthcare sector. Given TickrTrends' current assessment of MDT as fairly valued, this analyst action suggests the market price may have room to align with UBS's target, making the gap between current valuation and the target a metric worth monitoring for investors focused on fundamental value. The maintenance of coverage combined with an increased price target could indicate analyst expectations for earnings growth or operational improvements that would need to materialize for the valuation to shift from its current fairly valued position.

What people are saying

Follow the MDT conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — MDT's momentum indicator downgraded from D to none this week, while its sector discount rank declined from 59 to 64 among Healthcare companies. The stock remains fairly valued according to current valuation metrics. These changes suggest slightly weakening relative positioning within the Healthcare sector.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is MDT stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), MDT is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is MDT's TickrTrends verdict?

MDT's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does MDT compare to other Healthcare stocks?

MDT ranks #64 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is MDT overbought or oversold?

MDT's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

MDT vs A · MDT vs BAX · MDT vs DHR · MDT vs INVA · MDT vs IQV